Zobrazeno 1 - 10
of 19
pro vyhledávání: '"Louise Hopkins"'
Autor:
Kim Linton, Sridhar Chaganti, Kate Cwynarski, Josh Wright, Dominic Culligan, Roderick J. Johnson, Stefanie Thust, Ayesha S. Ali, Louise Hopkins, Aimee Jackson, Jeffery Smith, Andrew Davies, Andrés J.M. Ferreri, Shireen Kassam, Christopher P. Fox, Catherine Thomas, Ian Chau, David J. Lewis, Graham P. Collins, Nicolas Martinez-Calle, Dorothee P. Auer, Graham McIlroy
Publikováno v:
Fox, C P, Ali, A S, McIlroy, G, Thust, S, Martinez-Calle, N, Jackson, A E, Hopkins, L M, Thomas, C M, Kassam, S, Wright, J, Chaganti, S, Smith, J, Chau, I, Culligan, D, Linton, K M, Collins, G P, Ferreri, A J M, Lewis, D, Davies, A J, Johnson, R, Auer, D P & Cwynarski, K 2021, ' A phase 1/2 study of thiotepa-based immunochemotherapy in relapsed/refractory primary CNS lymphoma : the TIER trial ', Blood Advances, vol. 5, no. 20, pp. 4073-4082 . https://doi.org/10.1182/bloodadvances.2021004779
Relapsed or refractory primary central nervous system lymphoma (rrPCNSL) confers a poor prognosis with no accepted standard of care. Very few prospective studies have been conducted in this patient group. This study was a multicenter phase 1/2 study
Autor:
Justin Loke, Marlen Metzner, Eleni Tholouli, Andy Peniket, Charles Craddock, Louise Hopkins, Aimee Jackson, Rebecca H. Boucher, Rebecca Bishop, Mark Drummond, Jiri Pavlu, Sonia Fox, Paresh Vyas
Publikováno v:
British journal of haematologyReferences. 196(2)
Azacitidine (AZA) is important in the management of patients with acute myeloid leukaemia (AML) who are ineligible for intensive chemotherapy. Romidepsin (ROM) is a histone deacetylase inhibitor which synergises with AZA in vitro. The ROMAZA trial es
Autor:
Gabrielle G. Rees, L. R. Cherrill, C. Morland, C. Yap, David John Lewis, D. Slade, Louise Hopkins, Eszter Nagy, G. Turner, Andrew Davies, Christopher P. Fox, Kim Linton, Kate Cwynarski, Graham P. Collins, Stephen Booth
Publikováno v:
Collins, G P, Booth, S, Cherrill, L R, Slade, D, Morland, C, Hopkins, L, Nagy, E, Linton, K, Fox, C P, Lewis, D, Davies, A, Turner, G, Rees, G, Yap, C & Cwynarski, K 2021, ' ROMIDEPSIN AND CARFILZOMIB IN RELAPSED / REFRACTORY PERIPHERAL T-CELL LYMPHOMA WITH ASSESSMENT OF H23B AS A PREDICTIVE BIOMARKER – THE UK NCRI SEAMLESS PHASE 1/2 ROMICAR TRIAL ', Hematological oncology, vol. 39, no. S2 . https://doi.org/10.1002/hon.126_2880
Publikováno v:
BioTechniques, Vol 30, Iss 6, Pp 1262-1267 (2001)
Randomly amplified polymorphic DNA (RAPD) analysis using two or more primers has been reported to provide additional discriminatory ability over one primer used individually. This may be of particular application in epidemiological typing of clonal o
Externí odkaz:
https://doaj.org/article/1adb97c74aad4659b0253c038700d921
Autor:
(Justin) Ching Ting Loke, Charlotte Gaskell, Sonia Fox, Rachel Fletcher, Catherine Thomas, Louise Hopkins, Anita Kumari, Rebecca H. Boucher, Jane Nunnick, Steve Knapper, Arpad Toth, Jennifer Byrne, Jenny O'Nions, Anjum Khan, Rui Zhao, Arvind Pillai, Eleni Tholouli, Moez Dungarwalla, Katie Randall, Richard Dillon, Duncan Murray, Dominic Culligan, Mary Frances McMullin, Yuen Ling Tracey Chan, Victoria Drew, Vidhya Murthy, Pramila Krishnamurthy, Pratap Neelakantan, Tom Rider, Farooq A Wandroo, Mark Rafferty, Ya-Wen Huang, Sally Moore, Priyanka Mehta, David G Partridge, Charles Craddock, David Lowe, Simon J. Stanworth
Publikováno v:
Blood
The impact of Coronavirus disease 2019 (COVID-19) on outcomes in patients with cancer remains unclear. Acute Myeloid Leukemia (AML)/high-risk myelodysplasia (MDS) are common hematological malignancies resulting in profound immunosuppression, which is
Autor:
David John Lewis, Kim Linton, Matthew J. Ahearne, Charlotte Gaskell, Pam McKay, Nadia Nawaz, Christopher P. Fox, Aimee Jackson, Kate Cwynarski, Louise Hopkins, Andrew Davies, Matthew A. Timmins, Graham P. Collins, Clare Morland, Simon D. Wagner, Rod Johnson
Publikováno v:
Blood. 136:18-19
BACKGROUND Peripheral T-cell lymphomas (PTCL) are a diverse group of diseases, of which the majority of histological types respond poorly to first line treatments. While there are licensed treatments for refractory and relapsed PTCL responses are onl
Autor:
Kim Linton, David Wrench, Kate Cwynarski, Anesh Panchal, Andrew R. Pettitt, Catherine Hildyard, Toby A. Eyre, Angela Hamblin, Simon Rule, Ayesha S. Ali, Sharon Barrans, Daniel J. Royston, Graham P. Collins, Louise Hopkins, Aimee E Houlton, Andrew Davies, Martine P. Roudier, Caroline S. Hirst, Victoria Warbey, Elizabeth A. Harrington, Sally F. Barrington
Publikováno v:
HEMATOLOGICAL ONCOLOGY
Patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who are unfit for or relapsed postautologous stem-cell transplantation have poor outcomes. Historically, mTORC1 inhibitors have produced responses in approximately 30% of pati
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::342a9bcaf1271dcb55a698a64675561f
Autor:
Ian Chau, R. Johnson, Josh Wright, Ayesha S. Ali, Aimee Jackson, Christopher P. Fox, Jeffery Smith, Kim Linton, Kate Cwynarski, Shireen Kassam, Steffi Thust, Louise Hopkins, Andrés J.M. Ferreri, Andrew Davies, Sridhar Chaganti, Nicolas Martinez-Calle, David J. Lewis, Dominic Culligan, Dorothee P. Auer, Catherine Thomas, Graham P. Collins
Publikováno v:
Blood. 134:2879-2879
BACKGROUND Outcomes for patients (pts) with primary CNS diffuse large B cell lymphoma (PCNSL) have improved over recent years, largely through optimisation of first-line methotrexate (MTX)-containing protocols and dose-intensive chemotherapy consolid
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.